Carlsbad’s Ionis strikes deal with Japanese pharma worth up to $940M
Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine targeting a chronic blood disorder.
Investing3d
Ionis licenses olezarsen to Sobi for global reach
Additionally, a partnership with Ono Pharmaceuticals has been established to develop sapablursen for polycythemia vera, aiming to strengthen Ionis’s market presence. Oppenheimer has maintained ...
Investing3d
Ionis licenses olezarsen to Sobi for global reach
Additionally, a partnership with Ono Pharmaceuticals has been established to develop sapablursen for polycythemia vera, aiming to strengthen Ionis’s market presence. Oppenheimer has maintained an ...
Ionis Pharmaceuticals enters exclusive olezarsen license agreement with Sobi
Ionis Pharmaceuticals (IONS) announced that it has entered into a license agreement under which Sobi received exclusive rights in countries ...